Endocrine-focused biopharmaceutical company developing novel long-acting recombinant human growth hormone for growth hormone deficiency
Location: United States, California, Redwood City
Total raised: $121M
Investors 6
| Date | Name | Website |
| - | Aisling Ca... | aislingcap... |
| - | RA Capital... | racap.com |
| - | Sofinnova ... | sofinnova.... |
| - | Perceptive... | perceptive... |
| - | Advent Lif... | adventls.c... |
| - | New Leaf V... | nlvpartner... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 19.02.2014 | Series E | $55M | - |
| 08.10.2013 | Series D | $20M | - |
| 15.01.2013 | Series C | $25M | - |
| 17.02.2011 | Series B | $21M | - |
Mentions in press and media 15
| Date | Title | Description | Source |
| 25.10.2022 | Aravive Announces Approximately $41.5 Million Private Placem... | HOUSTON, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV) (“Company”), a late clinical... | globenewsw... |
| 25.10.2022 | Aravive Announces Approximately $41.5 Million Private Placem... | Priced At-The-Market with Substantial Participation from both New Life Sciences Specialist Investors... | einpresswi... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appeti... | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. B... | endpts.com... |
| 19.02.2014 | Cash-flush Versartis swings for an $80M IPO to advance its o... | On the same day it announced a $55 million E round, California biotech Versartis filed to go public ... | fiercebiot... |
| 19.02.2014 | Versartis Completes $55M Series E Financing | Versartis, Inc., a Redwood City, CA-based endocrine-focused biopharmaceutical company, completed a $... | finsmes.co... |
| 18.02.2014 | Versartis Secures $55M in Series E | REDWOOD CITY, CA, Endocrine-focused biopharmaceutical company today announced that it has complete... | vcnewsdail... |
| 08.10.2013 | Versartis nabs $20M in VC cash to take growth hormone to PhI... | California's Versartis is having quite a year, pulling down another $20 million in venture financing... | fiercebiot... |
| 08.10.2013 | Versartis Completes $20M Series D Financing | Versartis, Inc., a Redwood City, CA-based biotechnology company developing novel therapeutics for pa... | finsmes.co... |
| 29.01.2013 | Once-monthly HGH replacement therapy gets $25 million VC boo... | Versartis uses technology called XTEN to extend the half-life of proteins. It thinks compounds it de... | medcitynew... |
| 15.01.2013 | Versartis Completes $25M Series C Financing | Versartis, Inc., a Redwood City, CA-based biotechnology company developing novel therapeutics for pa... | finsmes.co... |
Show more